The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)
Objectives - To determine whether the tumor biomarkers cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), which are prognostic in early-stage non-small cell lung cancer (NSCLC), can predict which patients benefit from adjuvant chemotherapy (CTx). - Materials and methods - Serum...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
17 March 2018
|
| In: |
Lung cancer
Year: 2018, Volume: 120, Pages: 46-53 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2018.03.015 |
| Online Access: | Verlag, Pay-per-use, Volltext: https://doi.org/10.1016/j.lungcan.2018.03.015 Verlag, Pay-per-use, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500218303040 
|
| Author Notes: | Thomas Muley, Vinzent Rolny, Ying He, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc A. Schneider, Hendrik Dienemann, Michael Meister, Felix J. Herth, Farshid Dayyani |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1666350214 | ||
| 003 | DE-627 | ||
| 005 | 20220816161839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190527s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2018.03.015 |2 doi | |
| 035 | |a (DE-627)1666350214 | ||
| 035 | |a (DE-599)KXP1666350214 | ||
| 035 | |a (OCoLC)1341225521 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Muley, Thomas |e VerfasserIn |0 (DE-588)1056885432 |0 (DE-627)794179169 |0 (DE-576)16759284X |4 aut | |
| 245 | 1 | 4 | |a The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC) |c Thomas Muley, Vinzent Rolny, Ying He, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc A. Schneider, Hendrik Dienemann, Michael Meister, Felix J. Herth, Farshid Dayyani |
| 264 | 1 | |c 17 March 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.05.2019 | ||
| 520 | |a Objectives - To determine whether the tumor biomarkers cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), which are prognostic in early-stage non-small cell lung cancer (NSCLC), can predict which patients benefit from adjuvant chemotherapy (CTx). - Materials and methods - Serum samples were collected preoperatively from patients with NSCLC who underwent resection. Samples were retrospectively analyzed for CYFRA 21-1 and CEA via electrochemiluminescence immunoassay. Recurrence-free survival (RFS) was compared for patients who received adjuvant CTx versus surgery alone, stratified based on the following prognostic classifications: (1) tumor stage (pT1‐2/N0 [stage I] or pT3/N0 or pT1‐2/N1 [stage II]), (2) biomarker-based risk score, (3) clinical characteristics. Absolute 2-year RFS rates were calculated via Kaplan-Meier estimations; statistical significance level: 0.05. - Results - 227 patients were included (stage I: 69%; male: 67%; median age 65 years); 70 received adjuvant CTx. Median duration of sample collection was 58.8 months. All high-risk patients (by all three prognostic classifications) who received adjuvant CTx had a longer RFS versus those who received surgery alone. In patients with squamous cell carcinoma (SCC) classified as high risk by all three prognostic classifications, there was a benefit from adjuvant CTx versus surgery alone (tumor stage hazard ratio [HR] 4.9, p=0.004; biomarker levels HR 9.4, p=0.002; clinical characteristics HR 9.0, p=0.003). None of the prognostic classifications were able to predict a benefit from adjuvant CTx in patients with adenocarcinoma. - Conclusion - Baseline CYFRA 21-1 and CEA levels may provide further information to help clinicians decide which patients with SCC should receive adjuvant CTx. Further evaluation of these biomarkers is warranted. | ||
| 650 | 4 | |a Adjuvant chemotherapy | |
| 650 | 4 | |a CEA | |
| 650 | 4 | |a CYFRA 21-1 | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Squamous cell carcinoma | |
| 700 | 1 | |a Warth, Arne |d 1979- |e VerfasserIn |0 (DE-588)132646145 |0 (DE-627)524716927 |0 (DE-576)260019755 |4 aut | |
| 700 | 1 | |a Schneider, Marc |d 1982- |e VerfasserIn |0 (DE-588)140634401 |0 (DE-627)620239948 |0 (DE-576)319208095 |4 aut | |
| 700 | 1 | |a Dienemann, Hendrik |e VerfasserIn |0 (DE-588)1022899406 |0 (DE-627)717328104 |0 (DE-576)366145061 |4 aut | |
| 700 | 1 | |a Meister, Michael |e VerfasserIn |0 (DE-588)1078792046 |0 (DE-627)839461402 |0 (DE-576)451890108 |4 aut | |
| 700 | 1 | |a Herth, Felix |e VerfasserIn |0 (DE-588)1016095236 |0 (DE-627)705477568 |0 (DE-576)351509925 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 120(2018), Seite 46-53 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC) |
| 773 | 1 | 8 | |g volume:120 |g year:2018 |g pages:46-53 |g extent:8 |a The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC) |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2018.03.015 |x Verlag |x Resolving-System |z Pay-per-use |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0169500218303040 |x Verlag |z Pay-per-use |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190527 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1016095236 |a Herth, Felix |m 1016095236:Herth, Felix |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PH1016095236 |e 950000PH1016095236 |e 950900PH1016095236 |e 50000PH1016095236 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 11 | ||
| 998 | |g 1078792046 |a Meister, Michael |m 1078792046:Meister, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PM1078792046 |e 950000PM1078792046 |e 950900PM1078792046 |e 50000PM1078792046 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 10 | ||
| 998 | |g 1022899406 |a Dienemann, Hendrik |m 1022899406:Dienemann, Hendrik |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PD1022899406 |e 950000PD1022899406 |e 950900PD1022899406 |e 50000PD1022899406 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 9 | ||
| 998 | |g 140634401 |a Schneider, Marc |m 140634401:Schneider, Marc |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PS140634401 |e 950000PS140634401 |e 950900PS140634401 |e 50000PS140634401 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 8 | ||
| 998 | |g 132646145 |a Warth, Arne |m 132646145:Warth, Arne |d 910000 |d 912000 |e 910000PW132646145 |e 912000PW132646145 |k 0/910000/ |k 1/910000/912000/ |p 6 | ||
| 998 | |g 1056885432 |a Muley, Thomas |m 1056885432:Muley, Thomas |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PM1056885432 |e 950000PM1056885432 |e 950900PM1056885432 |e 50000PM1056885432 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1666350214 |e 3479820786 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"pubHistory":["1.1985 -"],"disp":"The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)Lung cancer","part":{"year":"2018","extent":"8","text":"120(2018), Seite 46-53","volume":"120","pages":"46-53"},"recId":"320649733","type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"journal of the International Association for the Study of Lung Cancer","title":"Lung cancer","title_sort":"Lung cancer"}],"language":["eng"],"note":["Gesehen am 20.02.20"],"id":{"eki":["320649733"],"zdb":["2025812-4"],"issn":["1872-8332"]},"origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"1985","dateIssuedDisp":"1985-","publisher":"Elsevier"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"role":"aut","family":"Muley","display":"Muley, Thomas","given":"Thomas"},{"given":"Arne","family":"Warth","display":"Warth, Arne","role":"aut"},{"display":"Schneider, Marc","family":"Schneider","role":"aut","given":"Marc"},{"given":"Hendrik","display":"Dienemann, Hendrik","family":"Dienemann","role":"aut"},{"family":"Meister","display":"Meister, Michael","role":"aut","given":"Michael"},{"given":"Felix","display":"Herth, Felix","family":"Herth","role":"aut"}],"recId":"1666350214","id":{"doi":["10.1016/j.lungcan.2018.03.015"],"eki":["1666350214"]},"origin":[{"dateIssuedDisp":"17 March 2018","dateIssuedKey":"2018"}],"name":{"displayForm":["Thomas Muley, Vinzent Rolny, Ying He, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc A. Schneider, Hendrik Dienemann, Michael Meister, Felix J. Herth, Farshid Dayyani"]},"note":["Gesehen am 27.05.2019"],"language":["eng"],"title":[{"title":"The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)","title_sort":"combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)"}],"physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a MULEYTHOMACOMBINATIO1720 | ||